Denali Therapeutics Inc

XNAS:DNLI 4:00:00 PM EDT

17.34

-0.64 (-3.56%)

6:03:04 PM EDT: $17.17 -0.17 (-0.98%)

Market Cap (Intraday)	2.54B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$3.08 Million
Adjusted EPS	-$0.75

See more estimates

10-Day MA	$18.27
50-Day MA	$16.96
200-Day MA	$15.01

See more pivots

Denali Therapeutics Inc Stock, XNAS:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 422

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.